Hundreds of thousands of people’s treatment at risk as countries ‘transition’ from Global Fund support

As ministers and leaders from member countries gather in Singapore this week, Japan and South Korea continue to push India and the ten member states of ASEAN to agree to IP provisions that undermine generic competition.

MSF calls on Global Fund Board to make urgent changes to prevent drug stock-outs and quality issues.

Groups pointed to the significant taxpayer money that J&J has received for the development and introduction of bedaquiline, and the need for these public investments to be reflected in the price of the drug.

We call on US pharma corporation Johnson & Johnson to cut key TB drug price in half